Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
LQWD Technologies Lightning Network Infrastructure Surpasses 1 Million Global Transactions (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Defence Therapeutics Inc C.DTC

Alternate Symbol(s):  DTCFF

Healthcare Biotechnology
Defence Therapeutics Inc. is a clinical-stage biotechnology company. The Company is engaged in developing and engineering the radio-immuno-conjugate and antibody drug conjugates (ADC) products using its proprietary platform in addition to immune-oncology vaccines. Its principal business activity is the development of a biological drug enhancer platform that improves the efficacy and safety of a... see more

Recent & Breaking News (CSE:DTC)

Defence Therapeutics Announces Securities for Debenture Financing

Newsfile 6 days ago

Defence Announces Radiopharmaceutical Expert Svetlana Selivanova Joins Board of Directors

Newsfile 8 days ago

Defence Announces Extension of Private Placement, Continues Development of Its Radiopharmaceuticals and ADC Programs

Newsfile November 4, 2024

Defence Therapeutics Completes 1st Tranche of Financing

Newsfile October 30, 2024

Defence's Corporate Updates, Arranges Financing

Newsfile September 27, 2024

Defence Appoints New Interim Chief Executive Officer

Newsfile August 30, 2024

Defence Investigates the Application of the Accum Hydrogel Technology to Deliver GLP-1 in Order to Increase the Treatment Efficacy of Diabetes and Weight Loss

Newsfile August 19, 2024

Defence Therapeutics Collaboration Agreement with Orano to Develop the Next Generation of Targeted Radio-Immunotherapy for Cancer Advances

Newsfile August 13, 2024

Defence Therapeutics Granted CNRI-H from the Canadian Nuclear Laboratories to Accelerate the Development of Its Radio-Immuno-Conjugates Program

Newsfile July 24, 2024

Defence Receives No Objection Letter from Health Canada for Phase I Trial of Its ACCUM-002 (AccuTOX) as an Anti-Cancer Molecule in Patients with Melanoma

Newsfile July 8, 2024

Defence Therapeutics touts anticancer treatment and immune booster

Jonathon Brown July 4, 2024

Defence's AccuTOX Boosts and Synergizes with Immune Checkpoint Inhibitors

Newsfile June 28, 2024

Defence's ARM-X Anti-Cancer Vaccine Inhibits Growth of Pre-Established Ovarian Cancer Resulting in Complete Responses in Treated Animals

Newsfile June 25, 2024

Defence's Chief Scientific Officer Dr. Moutih Rafei Discusses the Accum Platform for Cancer Treatments on Money Talk Radio with Ellis Martin

Newsfile June 17, 2024

CSE Bulletin: INDEX - CSE 25 INDEX QUARTERLY REBALANCING

Newsfile June 13, 2024

Defence to Participate in 2024 Society of Nuclear Medicine and Molecular Imaging Annual Meeting in Toronto on June 11, 2024

Newsfile June 10, 2024

Defence's AccuTOX Published in the Prestigious Journal of Translational Medicine Its Peer Study with Preclinical Data on AccuTOX as an Anti-Cancer Molecule

Newsfile June 6, 2024

Defence Therapeutics Strengthens and Expands Global Patent Protection on Key Technologies

Newsfile May 14, 2024

Pancreatic Cancer: Successful Trial Against Pancreatic Cancer with Defence Therapeutics' ARM-002 Anti-Cancer Vaccine

Newsfile May 1, 2024

Defence's AccuTOX Anti-Cancer ARM-002 Vaccine Exhibits Potent Antigen Presentation

Newsfile April 23, 2024